Insulin pens at an Eli Lilly plant in France. Photo: Frederick Florin/AFP via Getty Images

Eli Lilly's new "authorized generic" of its pricey Humalog insulin, called Lispro, is excluded from the 2019 national list of covered drugs from pharmacy benefit manager Express Scripts.

The big picture: So much for all the fanfare when Eli Lilly unveiled the insulin last month. Lispro's price doesn't change net spending on the insulin, even though it is cheaper for people paying cash out of pocket, and PBMs have little incentive to cover the drug if a rebate doesn't exist or is tiny.

Go deeper

The childless vaccine

Illustration: Eniola Odetunde/Axios

It'll likely be a long time before children are vaccinated against COVID-19, even though vaccinating kids could eventually play an integral role in reducing the virus' spread.

The big picture: None of the leading contenders in the U.S. are being tested for their effectiveness in children. Even once one of them gains authorization from the Food and Drug Administration, there will only be a limited number of available doses.

Progressives bide time for a Biden victory

Illustration: Sarah Grillo/Axios

Progressive Democrats want to beat President Trump so badly that they're tabling their apathy about Joe Biden — organizing hard to get him into office, only to fight him once elected.

Why it matters: That's a big difference from 2016, when progressives’ displeasure with Hillary Clinton depressed turnout and helped deliver the White House to Trump.

Election influence operations target journalists

Illustration: Aïda Amer/Axios

Foreign and domestic actors looking to influence the 2020 election are trying to trick real reporters into amplifying fake storylines. This tactic differs from 2016, when bad actors used fake accounts and bots to amplify disinformation to the population directly.

Why it matters: The new strategy, reminiscent of spy operations during the Cold War, is much harder for big tech platforms to police and prevent.